Supercharge Your Innovation With Domain-Expert AI Agents!

Treatment of lung cancer using a combination of an Anti-pd-1 antibody and another Anti-cancer agent

One-PD-1, PD-1 technology, applied in the field of lung cancer treatment

Pending Publication Date: 2018-09-28
BRISTOL MYERS SQUIBB CO
View PDF26 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is not yet known whether this combination of immunomodulatory antibodies is equally effective in other tumor types

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of lung cancer using a combination of an Anti-pd-1 antibody and another Anti-cancer agent
  • Treatment of lung cancer using a combination of an Anti-pd-1 antibody and another Anti-cancer agent
  • Treatment of lung cancer using a combination of an Anti-pd-1 antibody and another Anti-cancer agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0669] Treatment of NSCLC with Nivolumab Monotherapy or Nivolumab + Ililimumab and Platinum Double Chemotherapy

[0670] In the phase 3 CA209-227 study, treatment with nivolumab monotherapy or nivolumab in combination with ipilimumab was tested to determine overall survival (OS) compared with platinum doublet chemotherapy in chemotherapy-naïve subjects with stage IV or relapsed NSCLC. ) is improved. Formal pairwise comparisons of OS were performed between experimental groups.

[0671] The study also compared nivolumab monotherapy and the combination of nivolumab and ipilimumab with platinum-doublet chemotherapy in subjects with previously untreated stage IV or recurrent NSCLC, based on a blinded independent central review (BICR) assessment. Progression-free survival (PFS) and objective response rate (ORR). To assess the difference in PFS and ORR between nivolumab in combination with ipilimumab and nivolumab monotherapy in subjects with stage IV or relapsed NSCLC.

[0672] T...

Embodiment 2

[0745] Phase 3b / 4 dose frequency optimization of nivolumab 240 mg every 2 weeks versus nivolumab 480 mg every 4 weeks in subjects with advanced or metastatic non-small cell lung cancer who received 4 months of nivolumab 3 mg / kg or 240 mg every 2 weeks Research

[0746] Target

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anticancer agentwhich is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity which can be administered by infusion for less than 60 minutes; and, optionally, (b) another anti-cancer agent which is administered by infusion for less than 90 minutes. The other anti-cancer agent can be an anti- Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.

Description

field of invention [0001] The present invention relates to a method of treating lung cancer in a subject comprising administering to the subject a combination of an anti-cancer agent which is an anti-programmed death-1 (PD-1) antibody and optionally another anti-cancer agent . Background of the invention [0002] Human cancers have many genetic and epigenetic alterations that generate neoantigens that can potentially be recognized by the immune system (Sjoblom et al., 2006). The adaptive immune system, including T and B lymphocytes, has a powerful anticancer potential with broad capabilities and fine specificity in response to various tumor antigens. Furthermore, the immune system exhibits considerable plasticity and memory components. Successful exploitation of all these properties of the adaptive immune system will make immunotherapy unique among all cancer treatment modalities. [0003] Until recently, cancer immunotherapy has focused major efforts on approaches to enh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/00
CPCC07K16/2818A61K2039/545A61P11/00A61P35/00A61P43/00A61K2039/507C07K2317/33
Inventor F.纳桑
Owner BRISTOL MYERS SQUIBB CO
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com